Open Access

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

  • Authors:
    • Lyndsay V. Rhodes
    • Ashley M. Nitschke
    • H. Chris Segar
    • Elizabeth C. Martin
    • Jennifer L. Driver
    • Steven Elliott
    • Seung Yoon Nam
    • Meng Li
    • Kenneth P. Nephew
    • Matthew E. Burow
    • Bridgette M. Collins-Burow
  • View Affiliations

  • Published online on: October 4, 2011     https://doi.org/10.3892/or.2011.1488
  • Pages: 10-16
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic targeting in a number of ontological entities, particularly in the setting of aggressive therapy-resistant disease. Using the well-described HDAC inhibitor trichostatin A (TSA) we demonstrate the suppression of in vitro clonogenicity in the previously described apoptosis-resistant MCF-7TN-R breast carcinoma cell line. Additionally, recent work has demonstrated that these agents can alter the expression profile of microRNA signatures in malignant cells. Using an unbiased microRNA microarray analysis, changes in miRNA expression of MCF-7TN-R cells treated with TSA for 24 h were analyzed. We observed significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs in response to TSA treatment. Our results demonstrate that the HDACi, TSA, exerts anticancer activity in the apoptosis-resistant MCF-7TN-R breast carcinoma cell line. This activity is correlated with TSA alteration of microRNA expression profiles indicative of a less aggressive phenotype.

Related Articles

Journal Cover

January 2012
Volume 27 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Burow ME, et al: The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep 27: 10-16, 2012.
APA
Rhodes, L.V., Nitschke, A.M., Segar, H.C., Martin, E.C., Driver, J.L., Elliott, S. ... Collins-Burow, B.M. (2012). The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports, 27, 10-16. https://doi.org/10.3892/or.2011.1488
MLA
Rhodes, L. V., Nitschke, A. M., Segar, H. C., Martin, E. C., Driver, J. L., Elliott, S., Nam, S. Y., Li, M., Nephew, K. P., Burow, M. E., Collins-Burow, B. M."The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells". Oncology Reports 27.1 (2012): 10-16.
Chicago
Rhodes, L. V., Nitschke, A. M., Segar, H. C., Martin, E. C., Driver, J. L., Elliott, S., Nam, S. Y., Li, M., Nephew, K. P., Burow, M. E., Collins-Burow, B. M."The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells". Oncology Reports 27, no. 1 (2012): 10-16. https://doi.org/10.3892/or.2011.1488